BTK-话题@MedSci

#BTK#

73篇内容 | 2490人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539112, encodeId=db85153911296, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, objectType=article, longId=195498, objectId=094219549826, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=094219549826, replyNumber=0, likeNumber=65, createdTime=2020-06-10, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=094219549826, moduleTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=094219549826)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539111, encodeId=ed8615391110d, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, objectType=article, longId=194711, objectId=2e1a194e1115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1a194e1115, replyNumber=0, likeNumber=66, createdTime=2020-05-27, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1a194e1115, moduleTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1a194e1115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539110, encodeId=cdd315391101b, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, objectType=article, longId=192862, objectId=cb3a1928621f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3a1928621f, replyNumber=0, likeNumber=89, createdTime=2020-04-25, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3a1928621f, moduleTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3a1928621f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539109, encodeId=981b153910924, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴, objectType=article, longId=192295, objectId=7d35192295a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d35192295a3, replyNumber=0, likeNumber=80, createdTime=2020-04-16, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d35192295a3, moduleTitle=BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d35192295a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539108, encodeId=d18c153910856, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL, objectType=article, longId=191569, objectId=228219156976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228219156976, replyNumber=0, likeNumber=68, createdTime=2020-04-08, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228219156976, moduleTitle=Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228219156976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539107, encodeId=cac7153910ee3, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, objectType=article, longId=190747, objectId=c318190e4795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c318190e4795, replyNumber=0, likeNumber=62, createdTime=2020-03-26, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c318190e4795, moduleTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c318190e4795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539106, encodeId=a1dc153910662, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, objectType=article, longId=187657, objectId=c23618e6572f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23618e6572f, replyNumber=0, likeNumber=85, createdTime=2020-02-09, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23618e6572f, moduleTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c23618e6572f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539105, encodeId=de691539105a2, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, objectType=article, longId=185326, objectId=ed2f185326f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed2f185326f5, replyNumber=0, likeNumber=73, createdTime=2019-12-29, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed2f185326f5, moduleTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed2f185326f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539104, encodeId=09ee15391046c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, objectType=article, longId=184955, objectId=41c3184955ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c3184955ce, replyNumber=0, likeNumber=84, createdTime=2019-12-21, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c3184955ce, moduleTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c3184955ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=90, createdTime=2019-12-18, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539102, encodeId=f768153910276, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤, objectType=article, longId=183717, objectId=9ef0183e173f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ef0183e173f, replyNumber=0, likeNumber=71, createdTime=2019-11-30, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ef0183e173f, moduleTitle=BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ef0183e173f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539101, encodeId=08691539101dd, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=183460, objectId=fde3183460df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde3183460df, replyNumber=0, likeNumber=81, createdTime=2019-11-24, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde3183460df, moduleTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde3183460df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539100, encodeId=e92515391005f, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, objectType=article, longId=183115, objectId=e7431831158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7431831158c, replyNumber=0, likeNumber=80, createdTime=2019-11-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7431831158c, moduleTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7431831158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539099, encodeId=daf41539099d8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, objectType=article, longId=180451, objectId=021e180451ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=021e180451ba, replyNumber=0, likeNumber=66, createdTime=2019-10-05, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=021e180451ba, moduleTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=021e180451ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539098, encodeId=b2ef15390983e, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展, objectType=article, longId=178673, objectId=a1651e867369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1651e867369, replyNumber=0, likeNumber=78, createdTime=2019-09-04, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1651e867369, moduleTitle=新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1651e867369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539097, encodeId=3d05153909eb8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤, objectType=article, longId=178358, objectId=fc601e83580d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc601e83580d, replyNumber=0, likeNumber=64, createdTime=2019-08-31, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc601e83580d, moduleTitle=BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc601e83580d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539096, encodeId=18fb15390961f, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, objectType=article, longId=178216, objectId=e9211e8216cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9211e8216cb, replyNumber=0, likeNumber=62, createdTime=2019-08-28, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9211e8216cb, moduleTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9211e8216cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539095, encodeId=8216153909530, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, objectType=article, longId=177713, objectId=d3701e7713cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3701e7713cf, replyNumber=0, likeNumber=0, createdTime=2019-08-17, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3701e7713cf, moduleTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3701e7713cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539094, encodeId=80cd153909451, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定, objectType=article, longId=177712, objectId=28c91e77129a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c91e77129a, replyNumber=0, likeNumber=73, createdTime=2019-08-17, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c91e77129a, moduleTitle=阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c91e77129a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539093, encodeId=dde3153909346, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, objectType=article, longId=176194, objectId=46cc1e6194e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cc1e6194e7, replyNumber=0, likeNumber=55, createdTime=2019-07-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cc1e6194e7, moduleTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cc1e6194e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BTK

2020-05-29

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴

2020-06-10

fengting7 (审核中...)

前往app查看评论内容

#BTK#

EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好

2020-05-27

fengting7 (审核中...)

前往app查看评论内容

#BTK#

实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动

2020-04-25

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴

2020-04-16

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL

2020-04-08

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效

2020-03-26

fengting7 (审核中...)

前往app查看评论内容

#BTK#

复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点

2020-02-09

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL

2019-12-29

智慧医人 (审核中...)

前往app查看评论内容

#BTK#

头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

2019-12-21

fengting7 (审核中...)

前往app查看评论内容

#BTK#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤

2019-11-30

fengting7 (审核中...)

前往app查看评论内容

#BTK#

FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2019-11-24

fengting7 (审核中...)

前往app查看评论内容

#BTK#

百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物

2019-11-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔

2019-10-05

fengting7 (审核中...)

前往app查看评论内容

#BTK#

新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展

2019-09-04

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤

2019-08-31

fengting7 (审核中...)

前往app查看评论内容

#BTK#

百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查

2019-08-28

fengting7 (审核中...)

前往app查看评论内容

#BTK#

强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症

2019-08-17

fengting7 (审核中...)

前往app查看评论内容

#BTK#

阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定

2019-08-17

hb2008ye (审核中...)

前往app查看评论内容

#BTK#

Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性

2019-07-27

科室
- - 订阅+
  - 更多科室
工具
服务